SILVERBACK THERAPEUTICS INC (SBTX) Stock Overview
USA - NASDAQ:SBTX - US82835W1080 - Common Stock
SBTX Key Statistics, Chart & Performance
The current stock price of SBTX is 5.87 USD. In the past month the price increased by 12.24%. In the past year, price decreased by -30.53%.
SBTX Latest News, Press Relases and Analysis
SBTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.26 | 397.72B | ||
| AMGN | AMGEN INC | 13.38 | 157.08B | ||
| GILD | GILEAD SCIENCES INC | 15.31 | 147.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.63 | 106.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.51 | 69.20B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.13B | ||
| ARGX | ARGENX SE - ADR | 89.25 | 50.61B | ||
| INSM | INSMED INC | N/A | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.58B | ||
| NTRA | NATERA INC | N/A | 26.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.24 | 21.68B |
Related stock screener links
About SBTX
Company Profile
Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 90 full-time employees. The company went IPO on 2020-12-04. The firm is focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The Company’s lead virology product candidate, SBT8230, is an ASGR1-TLR8 ImmunoTAC therapeutic. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to a Toll-like receptor 8 (TLR8) linker-payload. SBT8230 is designed to elicit an anti-viral immune response by targeting TLR8 activation to the liver. SBT8230 antibody designed to recognize an epitope distinct from that bound by the ASGR1 ligand, GalNAc, allowing for possible combination of SBT8230. The Company’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.
Company Info
SILVERBACK THERAPEUTICS INC
500 Fairview Avenue North, Suite 600
Seattle WASHINGTON US
Employees: 90
Phone: 12064562900.0
SILVERBACK THERAPEUTICS INC / SBTX FAQ
What does SBTX do?
Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 90 full-time employees. The company went IPO on 2020-12-04. The firm is focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The Company’s lead virology product candidate, SBT8230, is an ASGR1-TLR8 ImmunoTAC therapeutic. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to a Toll-like receptor 8 (TLR8) linker-payload. SBT8230 is designed to elicit an anti-viral immune response by targeting TLR8 activation to the liver. SBT8230 antibody designed to recognize an epitope distinct from that bound by the ASGR1 ligand, GalNAc, allowing for possible combination of SBT8230. The Company’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.
What is the current price of SBTX stock?
The current stock price of SBTX is 5.87 USD. The price increased by 1.03% in the last trading session.
What is the dividend status of SILVERBACK THERAPEUTICS INC?
SBTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of SBTX stock?
SBTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is SILVERBACK THERAPEUTICS INC (SBTX) stock traded?
SBTX stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for SILVERBACK THERAPEUTICS INC?
SILVERBACK THERAPEUTICS INC (SBTX) operates in the Health Care sector and the Biotechnology industry.
SBTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SBTX. When comparing the yearly performance of all stocks, SBTX turns out to be only a medium performer in the overall market: it outperformed 62.07% of all stocks.
SBTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SBTX. While SBTX has a great health rating, there are worries on its profitability.
SBTX Financial Highlights
Over the last trailing twelve months SBTX reported a non-GAAP Earnings per Share(EPS) of -2.56. The EPS decreased by -6.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.5% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SBTX Forecast & Estimates
6 analysts have analysed SBTX and the average price target is 5.1 USD. This implies a price decrease of -13.12% is expected in the next year compared to the current price of 5.87.